Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC112
- Development stage
- Preclinical
- Lead developer
- HebeCell
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HC112 is an investigational, off-the-shelf cell therapy being developed by HebeCell for the treatment of solid tumors, specifically colorectal and ovarian cancers. The therapy consists of natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) that have been genetically engineered to express a chimeric antigen receptor (CAR). This approach leverages HebeCell's proprietary 3D-iPSC platform to generate standardized, high-purity CAR-NK cells at scale, aiming to overcome the limitations of patient-specific (autologous) therapies. HC112 is designed to recognize specific tumor-associated antigens and induce potent cytotoxic responses against cancer cells. It is currently in the preclinical stage of development.
Beyond the preview
Go deeper on HC112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC112.